2015 AAHKS Annual Meeting

Abstracts Archives

The following abstracts were presented at the podium during the 25th AAHKS Annual Meeting from November 5-8, 2015 at the Dallas Sheraton Hotel in Dallas, Texas, USA.

AAHKS Awards

The James A. Rand Young Investigator’s Award

A Randomized Controlled Trial of Oral and IV Tranexamic Acid: The Same Efficacy at Lower Cost? 
Young Investigator: Yale A. Fillingham, MD, Chicago, IL
Senior Author: Craig J. Della Valle, MD
Co-Authors: Erdan Kayupov, MS, Darren Plummer, MD, Mario Moric, MS, and Tad Gerlinger, MD

The Lawrence D. Dorr Surgical Techniques & Technologies Award

Conversion Total Hip Arthroplasty: Is it a Primary or Revision Hip Arthroplasty
Ran Schwarzkopf, MD, MSc, Scarsdale, NY
Co-Author: Mahta Baghoolizadeh, BS

The AAHKS Clinical Research Award

Liposomal Bupivacaine and Peri-articular Injection are Not Superior to Single Shot Intra-articular Injection for Pain Control in Total Knee Arthroplasty
Rajesh K. Jain, MD, MPH, Marlton, NJ
Co-Authors: Scott D. Schoifet, MD, FACS, Manny D. Porat, MD, Gregory G. Klingenstein, MD, Jeremy J. Reid, MD, Robert E. Post, MD

Abstracts in Numeric Order

  1. Alarming National Obesity Trends in Revision Total Knee Arthroplasty
    Susan M. Odum, PhD, Charlotte, NC
  2. Patients Improve Substantially Less after Revision Total Knee Arthroplasty for Flexion Instability vs. Failures Related to Infection or Wear-related Osteolysis
    Christopher W. Grayson, MD, Indianapolis, IN
  3. A Novel System for Determining Clinically Relevant Loosening of Total Knee Arthroplasty Components
    Brian P. Chalmers, MD, Rochester, MN
  4. Contribution of Surface Polishing and Sterilization Method to Backside Wear in Total Knee Replacement
    Edward M. Vasarhelyi, MD, MSc, FRCSC, London, ON, Canada
  5. Long Term Outcomes of 925 Extensively Porous-coated Stems in Revision Total Hip Arthroplasty
    Peter Keyes Sculco, MD, New York, NY
  6. Frequency and Treatment Trends for Periprosthetic Fractures about Total Hip Arthroplasty in the United States
    John S. Cox, MD, Portland, OR
  7. Obesity is a Risk Factor for Early Aseptic Loosening and Osteolysis of Hip Replacements
    Ali J. Electricwala, MD, Maharashta, India
  8. Revision of Monoblock MoM Total Hip Arthroplasty – Is There a Place for Dual Mobility Cup Extraction?
    Clint J. Wooten, MD, Charlotte, NC
  9. 10-Year Results of a Randomized Clinical Trial of Mobile-bearing vs. Fixed-bearing TKA
    Matthew P. Abdel, MD, Rochester, MN
  10. Total Knee Outcomes Correlate Strongly with Spine Disability
    William C. Schroer, MD, St. Louis, MO
  11. Does Pain and Function Differ after Primary TKR with Cemented vs. Cementless Fixation?
    David C. Ayers, MD, Worcester, MA
  12. Does Use of a Variable Distal Femur Resection Angle Improve Radiographic Alignment in Total Knee Arthroplasty?
    Dennis Nam, MD, MSc, St. Louis, MO
  13. No Improvement in Two-Year Functional Outcomes Using Kinematic vs. Mechanical Alignment in TKA – A Randomized Controlled Clinical Trial
    Simon W. Young, MBChB, FRACS, Auckland, New Zealand
  14. Differential Effect of Total Knee Arthroplasty on Valgus and Varus Knee Biomechanics During Gait
    Jose A. Rodriguez, MD, New York, NY
  15. Prior Lumbar Spinal Arthrodesis Increases Risk of Prosthetic-related Complication and Revision Surgery in Primary Total Hip Arthroplasty
    David C. Sing, BA, San Francisco, CA
  16. Validated Risk Stratification System for Pulmonary Embolism Following Primary Total Joint Arthroplasty
    Daniel D. Bohl, MD, New Haven, CT
  17. Individualized Risk Model for VTE Following TJA
    Ronald Huang, MD, New Haven, CT
  18. The Interaction of Obesity and Metabolic Syndrome in Determining Risk of Complication Following Total Joint Arthroplasty
    Adam I. Edelstein, MD, Chicago, IL
  19. Pre-operative Reduction of Opioid Use Prior to Total Joint Arthroplasty
    Long-Co Nguyen
  20. Long-acting Opioid Use Independently Predicts Perioperative Complication in Total Joint Arthroplasty
    Erik N. Hansen, MD, San Francisco, CA
  21. Formal Physical Therapy After Primary Total Hip Arthroplasty May Not Be Necessary
    Richard H. Rothman, MD, Philadelphia, PA
  22. Direct Anterior Approach Does Not Reduce Dislocation Risk
    Joseph D. Maratt, MD, Ann Arbor, MI
  23. Assessment of the Impact of Anterior vs. Posterior Surgical Approach for Total Hip Arthroplasty on Post-acute Care Service Utilization
    Coles E. L’Hommedieu, MD, St. Louis, MO
  24. Evaluation of Highly Cross-linked Polyethylene Articulating with 28mm and 36mm Heads Using Radiostereometric Analysis (RSA)
    Harry E. Rubash, MD, Boston, MA
  25. Minimum 10 year Multi-center Study of THR with Highly Cross-linked Polyethylene and Large Diameter Femoral Heads
    Charles R. Bragdon, PhD, Boston, MA
  26. A Multi-center, Prospective, Randomized Study of Outpatient vs. Inpatient Total Hip Arthroplasty
    Nitin Goyal, MD, Alexandria, VA
  27. Oral Antibiotics Reduce Reinfection Following 2-stage Exchange: A Multi-center, Randomized Controlled Trial
    Craig J. Della Valle, MD, Chicago, IL
  28. The Alpha-defensin Test for PJI is Not Affected by Prior Antibiotic Administration
    Carl A. Deirmengian, MD, Philadelphia, PA
  29. Articulating vs. Static Spacers in the Management of Periprosthetic Knee Infection: A Randomized Clinical Trial
    Peter N. Chalmers, MD, Chicago, IL
  30. What is the Benefit of Staphylococcal Screening and Treatment Prior to Elective Hip/Knee Arthroplasty?
    Scott M. Sporer, MD, MS, Winfield, IL
  31. Do Injections Increase the Risk of Infection Following TKA?
    Nicholas A. Bedard, MD, Iowa City, IA
  32. The Timing of THA after Intra-articular Hip Injection affects Postoperative Infection Risk
    Jourdan M. Cancienne, MD, Charlottesville, VA
  33. Prospective Comparison of Tranexamic Acid vs. a Bipolar Sealer in Reducing Blood Loss in Primary Total Knee Arthroplasty
    Stephen M. Walsh, MD, Bangor, ME
  34. Tranexamic Acid Reduced Blood Loss but not Transfusion after Hip Arthroplasty for Femoral Neck Fracture: A Randomized Clinical Trial of 138 Patients
    Chad D. Watts, MD, Rochester, MN
  35. Hypoalbuminemia Predicts Joint Infection, Pneumonia, and Readmission after Total Joint Arthroplasty
    Erdan Kayupov, MD, Chicago, IL
  36. Peri-articular Liposomal Bupivacaine Offers No Benefit over Bupivacaine in Total Knee Arthroplasty
    Matthew S. Austin, MD, Philadelphia, PA
  37. A Randomized Controlled Trial Comparing Adductor Canal and Intra-articular Catheters for Pain Management after Primary Total Knee Arthroplasty
    Antonia F. Chen, MD, MBA, Philadelphia, PA
  38. Can Short but Reliable Measures of Knee-specific Function be Constructed Using Item Response Theory?
    Barbara Gandek, PhD, Worcester, MA
  39. Avascular Necrosis a Genetic Disease? A Genome-wide Association Study
    Cody C. Wyles, BS, Rochester, MN
  40. Economic Impact of Ketorolac vs. Corticosteroid Intra-articular Knee Injections for Osteoarthritis
    Siraj A. Sayeed, MD, Fort Sam Houston, TX
  41. Average 10 Year Results of the Bernese Periacetabular Osteotomy for Severe Acetabular Dysplasia
    Stephen T. Duncan, MD, Lexington, KY
  42. Femoral Morphology in Acetabular Dysplasia: Are Cam-Lesions Common?
    Russell P. Swann, Indianapolis, IN
  43. When Hip Scopes Fail, They Do So Quickly
    John J. Callaghan, MD, Iowa City, IA
  44. Hip Arthroscopy Failure in the Setting of Acetabular Dysplasia: A Concerning Trend?
    Jacob A. Haynes, MD, St. Louis, MO
  45. Safe Selection of Outpatient Joint Replacement Patients with Medical Risk Stratification: The “OARA Score”
    R. Michael Meneghini, MD, Fishers, IN
  46. Comparing Primary Total Hip Arthroplasty Post-discharge Care Duration, Costs, and Outcomes
    Karthikeyan E. Ponnusamy, MD, Baltimore, MD
  47. We Can Safely Reduce the Utilization of Home Visiting Nurse Services Following Primary Total Joint Arthroplasty
    James J. Purtill, MD, Philadelphia, PA
  48. Risk Reduction Efforts Do Not Decrease 30-day Primary Hip and Knee Readmissions for Disadvantaged CMS Patients
    James A. Keeney, MD, Columbia, MD
  49. Medicare’s Hospital Acquired Conditions Policy: A Problem of Non-Payment After Total Joint Arthroplasty
    Kyle R. Duchman, MD, Iowa City, IA
  50. Differences in Hospital Billing for Total Joint Arthroplasty Based on Hospital Profit Status
    Brett M. Hall, MD, San Antonio, TX
  51. The Effect of the Medicare 3-Day Rule on Patient Length of Stay and Disposition after Total Hip Arthroplasty
    Victor H. Hernandez, MD, Miami, FL
  52. What is the Natural History of “Asymptomatic” Pseudotumours in MoM THA Minimum 4-year MARS MRI Longitudinal Study
    Young-Min Kwon, MD, PhD, Boston, MA
  53. National Trends in Bearing Surface Usage of Primary Total Hip Arthroplasty in Extremely Young Patients From 2009-2012
    Eric L. Smith, MD, Boston, MA
  54. The Effect of Flexural Rigidity, Taper Angle, and Contact Length on Fretting and Corrosion at the Head-neck Junction
    Y. Julia Kao, MD, Atlanta, GA
  55. Effect of Contamination on Torque Testing of the Taper Junction in Total Hip Arthroplasty
    Ryan M. Palmer, DO, Dublin, OH
  56. Does Taper Design Have an Effect on Taper Damage in Retrieved Total Hip Devices?
    Genymphas Higgs, Philadelphia, PA



Each participant in the Annual Meeting has been asked to disclose if he or she has received something of value from a commercial company or institution, which relates directly or indirectly to the subject of their presentation. The AAOS has identified the options to disclose as follows:

n = nothing to disclose;
1 = Royalties from a company or supplier;
2 = Speakers bureau/paid presentations;
for a company or supplier;
3A = Paid employee for a company or supplier;
3B = Paid consultant for a company or supplier;
3C = Unpaid consultant for a company or supplier;
4 = Stock or stock options in a company or supplier;
5 = Research support from a company or supplier as a PI;
6 = Other financial or material support from a company or supplier;
7 = Royalties, financial or material support from publishers;
8 = Medical/Orthopaedic publications, editorial/governing board;
9 = Board member/committee appointments for a society.

Click here to download a listing of the disclosures. An indication of the participant’s disclosure appears after his or her name as well as the commercial company or institution that provided the support. AAOS and AAHKS do not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in the course.

Close Bitnami banner